PRACTICE AREA OVERVIEW
Dr. Morlock prepares and prosecutes U.S. and international patent applications.
Dr. Morlock has prepared and prosecuted patent applications covering biotechnology and pharmaceutical technologies including diagnostic methods, pharmaceutical compositions and excipients, immune therapies, antibody therapeutics, and metabolic engineering.
PRIOR PROFESSIONAL EXPERIENCE
Landon IP (CPA Global), Remote
Patent Analyst | 2016 – 2017
Mintz Levin, San Francisco, CA and Boston
Patent Agent | 2016 – 2016
Alleman, Hall, McCoy, Russell & Tuttle, Portland, OR
Technical Consultant | 2012 – 2013
University of Wisconsin – Madison, Madison, WI
Graduate Research Fellow | 2007 – 2012
Wisconsin Alumni Research Foundation, Madison, WI
Patent Mining Intern | 2009 – 2010
Dartmouth Medical School, Hanover, NH
Laboratory Technician | 2006, 2007
Cal Poly, San Luis Obispo, CA
Student Research | 2006 – 2007
PRESENTATIONS AND PUBLICATIONS
- Elaine V. Morlock et al. HSD3B and Gene-Gene Interactions in a Pathway-Based Analysis of Genetic Susceptibility to Bladder Cancer. PLoS ONE. Epub December 2012.
- “Benzodiazepine actions: Teasing apart drug binding from drug efficacy,” American Society for Pharmacology and Experimental Therapeutics Annual Meeting, April 2014
- Elaine V. Morlock and Cynthia Czajkowski. Different Residues in the GABAA Receptor Benzodiazepine Binding Pocket Mediate Benzodiazepine Efficacy and Binding. Mol Pharmacol. July 2011. Vol. 80. p. 14-22.
- “Disulfide tethering GABA-A receptor beta subunit loop 9 inhibits channel activation,” Society for Neuroscience Annual Meeting, November 2010
- “Defining residues involved in the efficacy of benzodiazepine modulation of GABAA receptor current,” Society for Neuroscience Annual Meeting, October 2009
- Elaine V. Morlock et al. EGFR Pathway Polymorphisms and Bladder Cancer Susceptibility and Prognosis. Carcinogenesis. July 2009. Vol. 30 p. 1155-1160.
- Elaine V. Morlock et al. SNPs Associated with Bladder Cancer Risk and Prognosis: a Genome-wide Analysis. Hum. Genet. June 2009. Vol 125. p. 527-539.
- “EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis,” American Association for Cancer Research Conference, April 2009
- “Defining the pharmacophore for eszopiclone and zolpidem on the GABAA receptor,” Society for Neuroscience Annual Meeting, November 2008
- Elaine V. Morlock et al. Structural Requirements for Eszopiclone and Zolpidem Binding to the y-aminobutyric acid Type A (GABAA) Receptor are Different. J. Med. Chem. Nov. 2008. Vol. 51. p. 7243–7252.
- “Genome-wide analysis of SNPs associated with TP53 protein dysregulation in bladder tumors,” American Association of Cancer Research – Frontiers in Cancer Prevention Research Conference, November 2006